MKI67 and breast carcinoma: However, the net result of cell cycling is cell proliferation, and therefore immunohistochemical (IHC) analysis of Ki67 using the MIB-1 antibody has emerged as the marker of choice with both prognostic and treatment predictive value in breast cancer [7,8].